PAIM
HBIO icon

Punch & Associates Investment Management’s Harvard Bioscience HBIO Stock Holding History

Punch & Associates Investment Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,559
Closed -$14.5K – 170
2025
Q1 		$14.5K Sell
2,559
-273,001
-99% -$3.5M ﹤0.01% 159
2024
Q4 		$5.81M Sell
275,560
-1,710
-0.6% -$39.3K 0.32% 111
2024
Q3 		$7.46M Buy
277,270
+36
+0% +$1.06K 0.41% 105
2024
Q2 		$7.9M Hold
277,234
– – 0.46% 96
2024
Q1 		$11.8M Sell
277,234
-14,569
-5% -$655K 0.67% 52
2023
Q4 		$15.6M Sell
291,803
-500
-0.2% -$22.6K 0.91% 26
2023
Q3 		$12.6M Buy
292,303
+6,038
+2% +$279K 0.81% 30
2023
Q2 		$15.7M Sell
286,265
-8,468
-3% -$465K 0.96% 27
2023
Q1 		$12.4M Buy
294,733
+18,329
+7% +$544K 0.8% 36
2022
Q4 		$7.66M Buy
276,404
+4,057
+1% +$100K 0.5% 87
2022
Q3 		$6.97M Buy
272,347
+6,922
+3% +$229K 0.49% 86
2022
Q2 		$9.55M Buy
265,425
+18,884
+8% +$852K 0.67% 48
2022
Q1 		$15.3M Buy
246,541
+29,863
+14% +$1.77M 0.87% 25
2021
Q4 		$15.3M Buy
216,678
+54,500
+34% +$3.88M 0.8% 31
2021
Q3 		$11.3M Sell
162,178
-5,253
-3% -$418K 0.65% 50
2021
Q2 		$13.9M Sell
167,431
-3,856
-2% -$273K 0.79% 33
2021
Q1 		$9.35M Buy
171,287
+10,103
+6% +$491K 0.56% 68
2020
Q4 		$6.92M Buy
161,184
+7,404
+5% +$276K 0.48% 89
2020
Q3 		$4.63M Buy
153,780
+52,300
+52% +$1.76M 0.4% 102
2020
Q2 		$3.15M Buy
+101,480
New +$2.73M 0.28% 125
2015
Q4 		– Sell
-36,065
Closed -$1.36M – 275
2015
Q3 		$1.36M Hold
36,065
– – 0.19% 157
2015
Q2 		$2.06M Hold
36,065
– – 0.26% 143
2015
Q1 		$2.1M Hold
36,065
– – 0.26% 135
2014
Q4 		$2.04M Hold
36,065
– – 0.26% 138
2014
Q3 		$1.48M Sell
36,065
-9,690
-21% -$446K 0.21% 148
2014
Q2 		$2.08M Hold
45,755
– – 0.28% 136
2014
Q1 		$2.17M Hold
45,755
– – 0.3% 132
2013
Q4 		$2.15M Sell
45,755
-14,596
-24% -$638K 0.29% 136
2013
Q3 		$2.41M Hold
60,351
– – 0.37% 120
2013
Q2 		$2.15M Buy
+60,351
New +$2.31M 0.38% 126

Other funds holding HBIO

AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Punch & Associates Investment Management's HBIO Position: Q2 2025 in Review

Punch & Associates Investment Management sold out of Harvard Bioscience (HBIO) in Q2 2025, closing a stake of 2,559 shares — an estimated $14.5K sold.

Punch & Associates Investment Management first reported a position in HBIO in Q2 2013 and held it in 30 quarters. The position peaked at $15.7M in Q2 2023. 69 funds tracked by Wall St. Rank hold HBIO as of Q2 2025.

  • Punch & Associates Investment Management reported no remaining Harvard Bioscience position as of Q2 2025 after selling out during the quarter.
  • Punch & Associates Investment Management sold 2,559 Harvard Bioscience shares in Q2 2025, an estimated $14.5K.
  • Punch & Associates Investment Management first reported a position in Harvard Bioscience in Q2 2013 and held it in 30 quarters.
  • Punch & Associates Investment Management's Harvard Bioscience position peaked at $15.7M in Q2 2023.
  • 69 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2025.

Based on Punch & Associates Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.